# A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)

> **NCT05121948** · PHASE1 · TERMINATED · sponsor: **HiberCell, Inc.** · enrollment: 35 (actual)

## Conditions studied

- Squamous Cell Carcinoma of Head and Neck
- Colo-rectal Cancer
- Non Small Cell Lung Cancer
- Transitional Cell Carcinoma of the Bladder
- Other Solid Tumors
- Clear Cell Renal Cell Carcinoma

## Interventions

- **DRUG:** HC-7366

## Key facts

- **NCT ID:** NCT05121948
- **Lead sponsor:** HiberCell, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-02-23
- **Primary completion:** 2024-02-09
- **Final completion:** 2024-03-01
- **Target enrollment:** 35 (ACTUAL)
- **Why stopped:** sponsor decision
- **Last updated:** 2024-03-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05121948

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05121948, "A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05121948. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*